The trajectory of Sildenafil presents a complex case for investors in the medicinal sector. While initially a phenomenal success, generating vast sums, the patent end and the subsequent arrival of off-brand alternatives have considerably changed income. This raises questions about the long-term sustainability of related medication projects and sugg